CNSX:VYGR

Voyager Therapeutics Stock Forecast, Price & News

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

VolumeN/A

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Receive VYGR News and Ratings via Email

Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Voyager Therapeutics

Voyager Digital Ltd., through its subsidiaries, engages in the development and commercialization of a digital platform that enables users to buy and sell digital assets (cryptocurrencies) across multiple exchanges in one account primarily in the United States and Canada. The company was founded in 2018 and is headquartered in New York, New York.

Voyager Therapeutics (CNSX:VYGR) Coverage Initiated by Analysts at Eight Capital
July 28, 2021 | americanbankingnews.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange CNSX
Industry Software—Application
Sub-IndustryN/A
SectorComputer and Technology
Current SymbolCNSX:VYGR
Previous Symbol
CUSIPN/A
CIK1640266
Webwww.investvoyager.com
Phone212 547 8807
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.00 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Voyager Therapeutics.

5.0 Community Rank

Outperform Votes
Voyager Therapeutics has received 2 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Voyager Therapeutics has received 0 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Voyager Therapeutics has received 100.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Voyager Therapeutics and other stocks. Vote “Outperform” if you believe VYGR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VYGR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Voyager Therapeutics does not currently pay a dividend.
Dividend Growth
Voyager Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Voyager Therapeutics insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Voyager Therapeutics (CNSX:VYGR) Frequently Asked Questions

Is Voyager Therapeutics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last twelve months. There are currently 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "strong buy" Voyager Therapeutics stock.
View analyst ratings for Voyager Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Voyager Therapeutics?

Wall Street analysts have given Voyager Therapeutics a "Strong Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Voyager Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Voyager Therapeutics' key executives?

Voyager Therapeutics' management team includes the following people:

Mr. Philip Eytan, Co-Founder & Non-Exec. Independent Chairman (Age 44)
Mr. Stephen Ehrlich, Co-Founder, CEO & Director (Age 54)
Mr. Gaspard de Dreuzy, Co-Founder (Age 45)
Mr. Oscar Salazar, Co-Founder & Technical Advisor (Age 43)
Mr. Evan Psaropoulos, Chief Financial Officer
Mr. Gerard Hanshe, Chief Operating Officer (Age 44)
Mr. Daniel Costantino CISM, CISSP, Chief Information Security Officer
Ms. Janice Jones Barrilleaux, Chief Compliance Officer (Age 54)
Mr. David Brosgol, Gen. Counsel
Mr. Michael Frederick Legg Sr., Chief Communications Officer

Who are some of Voyager Therapeutics' key competitors?

Some companies that are related to Voyager Therapeutics include 9 Spokes International (9SP), accesso Technology Group (LOQPF), Advanced Human Imaging (AHI), Advant-e (ADVC), Aerometrex (AMX), Ansarada Group (AND), AppsVillage Australia (APV), AppSwarm (SWRM), APT Systems (APTY), BM Technologies (BMTX), Cape Range (CAG), Cashwerkz (CWZ), Complii FinTech Solutions (CF1), Damstra (DTC) and Digihost Technology (HSSHF).
View all of VYGR's competitors.

What is Voyager Therapeutics' stock symbol?

Voyager Therapeutics trades on the CNSX under the ticker symbol "VYGR."

How do I buy shares of Voyager Therapeutics?

Shares of VYGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Voyager Therapeutics' official website?

The official website for Voyager Therapeutics is www.investvoyager.com.

How can I contact Voyager Therapeutics?

The company can be reached via phone at 212 547 8807.

This page was last updated on 7/29/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.